BRPI0614493B8 - uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto - Google Patents
uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido compostoInfo
- Publication number
- BRPI0614493B8 BRPI0614493B8 BRPI0614493A BRPI0614493A BRPI0614493B8 BR PI0614493 B8 BRPI0614493 B8 BR PI0614493B8 BR PI0614493 A BRPI0614493 A BR PI0614493A BR PI0614493 A BRPI0614493 A BR PI0614493A BR PI0614493 B8 BRPI0614493 B8 BR PI0614493B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- het
- hydrogen
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- -1 quinoline derivative compound Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto. uso de um composto para a fabricação de um medicamento para o tratamento de uma infecção bacteriana desde que a infecção bacteriana seja diferente de uma infecção micobacteriana, o referido composto sendo um composto de fórmula (1), um saí de adição de ácido ou base farmaceuticamente aceitável, uma amina quaternária, uma forma estereoquimicamente isomérica, uma forma tautomérica ou uma forma n-óxido do mesmo, em que r1 é hidrogênio, halo, haloalquila, ciano, hidróxi, ar, het, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioalquila, ar-alquila ou di (ar) alquila; p é 1 a 3; s é 0 a 4; r2 é hidrogênio; halo; alquila; hidróxi; mercapto; alquilóxi opcionaímente substituído; alquiloxialquilóxi; alquiltio; mono ou di (alquil) amino em que alquila pode ser opcionalmente substituida; ar; het ou um radical de fórmula ; r3 é alquila, ar, ar-alquila, het ou het-alquila; q é 0 a 4; r4 e r5 cada independentemente são hidrogênio, alquila ou benzila; ou e podem ser tomados juntos incluindo o n aos quais eles são fixados; r6 é hidrogénio, halo, haloalquila, hidróxi, ar, alquila, alquilóxi, alquiltio, alquiloxial- quila, alquiltioalquila, ar-alquila ou di (ar) alquila; ou dois radicais r6 vicinais podem ser tomados juntos para formar juntos com o anel fenila aos quais eles são fixados uma naftila; r é 1 a 5; r7 é hidrogênio, alquila, ar ou het; r8 é hidrogênio, alquila, hidroxila, aminocarbonila, mono-ou di (alquil) amino-carbonila, ar, het, alquila substituida por um ou dois het, alquila substituida por um ou dois ar, het-c(=o)- ou ar-c(=o)-; desde que quando o radical contendo r3 é colocado na posição 3 da porção quinolina; r7 é colocado na posição 4 e r2 é colocado na posição 2 e representa hidrogênio, hidróxi, mercapto, alquilóxi, alquiloxialquilóxi, alquiltio, mono ou di (alquil) amino ou um radical de fórmula (iii), então s é 1 a 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107164 | 2005-08-03 | ||
| EP05107164.5 | 2005-08-03 | ||
| PCT/EP2006/064858 WO2007014941A2 (en) | 2005-08-03 | 2006-07-31 | Quinoline derivatives as antibacterial agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0614493A2 BRPI0614493A2 (pt) | 2011-03-29 |
| BRPI0614493B1 BRPI0614493B1 (pt) | 2019-11-12 |
| BRPI0614493B8 true BRPI0614493B8 (pt) | 2021-05-25 |
Family
ID=35744723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614493A BRPI0614493B8 (pt) | 2005-08-03 | 2006-07-31 | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8802671B2 (pt) |
| EP (1) | EP1912648B1 (pt) |
| JP (1) | JP5302680B2 (pt) |
| KR (1) | KR101413997B1 (pt) |
| CN (2) | CN101277696B8 (pt) |
| AP (1) | AP2654A (pt) |
| AR (1) | AR054890A1 (pt) |
| AU (1) | AU2006274880B2 (pt) |
| BR (1) | BRPI0614493B8 (pt) |
| CA (1) | CA2615903C (pt) |
| CY (1) | CY1114318T1 (pt) |
| DK (1) | DK1912648T3 (pt) |
| EA (1) | EA014833B1 (pt) |
| ES (1) | ES2414956T3 (pt) |
| HK (1) | HK1124234A1 (pt) |
| HR (1) | HRP20130540T1 (pt) |
| IL (1) | IL189142A0 (pt) |
| JO (1) | JO2855B1 (pt) |
| ME (1) | ME01616B (pt) |
| MX (1) | MX2008001603A (pt) |
| MY (1) | MY159560A (pt) |
| NO (1) | NO341242B1 (pt) |
| NZ (1) | NZ565947A (pt) |
| PL (1) | PL1912648T3 (pt) |
| PT (1) | PT1912648E (pt) |
| RS (1) | RS52808B (pt) |
| SI (1) | SI1912648T1 (pt) |
| TW (1) | TWI422374B (pt) |
| UA (1) | UA95915C2 (pt) |
| WO (1) | WO2007014941A2 (pt) |
| ZA (1) | ZA200801110B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004186452A (ja) | 2002-12-04 | 2004-07-02 | Renesas Technology Corp | 不揮発性半導体記憶装置およびその製造方法 |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| KR20150070348A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
| PL2909192T3 (pl) | 2012-10-16 | 2017-09-29 | Janssen Pharmaceutica Nv | Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| WO2015057629A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | ALKYL LINKED QUINOLINYL MODULATORS OF RORyt |
| CN109111396B (zh) * | 2018-08-28 | 2021-09-03 | 广东工业大学 | 一种喹啉芳香乙烯衍生物及其制备方法和应用 |
| CN109111397B (zh) * | 2018-08-28 | 2021-12-10 | 广东工业大学 | 一种喹啉芳香乙烯类衍生物及其制备方法和应用 |
| CN112110907B (zh) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | 一种含1，4-二氧六环二聚双噻吩结构的化合物及其制备方法和应用 |
| CN112079825B (zh) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | 含1，3-二氧戊环二聚双噻吩结构的化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB807750A (en) * | 1956-06-15 | 1959-01-21 | Rhone Poulenc Sa | Improvements in or relating to piperazine derivatives |
| GB9317491D0 (en) * | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
| CA2270123A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| PT2301544E (pt) * | 2002-07-25 | 2012-12-10 | Janssen Pharmaceutica Nv | Novos inibidores de micobactérias |
| PL360102A3 (en) | 2003-05-13 | 2004-11-15 | "ENERGOMAR-NORD" Sp.z o.o. | Method for manufacturing highly reactive calcium sorbing agents and facility designed for manufacturing highly reactive calcium sorbing agents |
| UA85570C2 (uk) | 2004-01-23 | 2009-02-10 | Янссен Фармацевтика Н.В. | Заміщені хіноліни та їх застосування як мікобактеріальних інгібіторів |
| RS51074B (sr) | 2004-01-23 | 2010-10-31 | Janssen Pharmaceutica N.V. | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
| AP2321A (en) * | 2004-01-29 | 2011-11-16 | Janssen Pharmaceutica Nv | Quinoline derivatives for use as mycobactrial inhibitor. |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| US20070018948A1 (en) | 2005-07-22 | 2007-01-25 | Elaine Chen | Apparatus for stabilizing an electronic device during data input and device control |
-
2006
- 2006-07-18 JO JO2006232A patent/JO2855B1/en active
- 2006-07-31 DK DK06778083.3T patent/DK1912648T3/da active
- 2006-07-31 PL PL06778083T patent/PL1912648T3/pl unknown
- 2006-07-31 EA EA200800508A patent/EA014833B1/ru unknown
- 2006-07-31 ES ES06778083T patent/ES2414956T3/es active Active
- 2006-07-31 MX MX2008001603A patent/MX2008001603A/es active IP Right Grant
- 2006-07-31 RS RS20130254A patent/RS52808B/en unknown
- 2006-07-31 UA UAA200801432A patent/UA95915C2/ru unknown
- 2006-07-31 NZ NZ565947A patent/NZ565947A/en not_active IP Right Cessation
- 2006-07-31 WO PCT/EP2006/064858 patent/WO2007014941A2/en active Application Filing
- 2006-07-31 ME MEP-2013-65A patent/ME01616B/me unknown
- 2006-07-31 JP JP2008524509A patent/JP5302680B2/ja active Active
- 2006-07-31 AP AP2008004316A patent/AP2654A/xx active
- 2006-07-31 SI SI200631602T patent/SI1912648T1/sl unknown
- 2006-07-31 US US11/997,173 patent/US8802671B2/en active Active
- 2006-07-31 PT PT67780833T patent/PT1912648E/pt unknown
- 2006-07-31 AU AU2006274880A patent/AU2006274880B2/en not_active Ceased
- 2006-07-31 CA CA2615903A patent/CA2615903C/en active Active
- 2006-07-31 KR KR1020087005071A patent/KR101413997B1/ko active IP Right Grant
- 2006-07-31 CN CN200680036751.2D patent/CN101277696B8/zh active Active
- 2006-07-31 BR BRPI0614493A patent/BRPI0614493B8/pt not_active IP Right Cessation
- 2006-07-31 EP EP06778083.3A patent/EP1912648B1/en active Active
- 2006-07-31 CN CNA2006800367512A patent/CN101277696A/zh active Granted
- 2006-08-01 MY MYPI20063727A patent/MY159560A/en unknown
- 2006-08-02 TW TW095128224A patent/TWI422374B/zh active
- 2006-08-02 AR ARP060103372A patent/AR054890A1/es unknown
-
2008
- 2008-01-31 IL IL189142A patent/IL189142A0/en active IP Right Grant
- 2008-02-01 ZA ZA2008/01110A patent/ZA200801110B/en unknown
- 2008-02-27 NO NO20081026A patent/NO341242B1/no not_active IP Right Cessation
-
2009
- 2009-02-05 HK HK09101045.4A patent/HK1124234A1/zh not_active IP Right Cessation
-
2013
- 2013-06-14 HR HRP20130540TT patent/HRP20130540T1/hr unknown
- 2013-07-09 CY CY20131100578T patent/CY1114318T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0614493B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto | |
| BRPI0614524B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto | |
| BRPI0507065A (pt) | derivados de quinolina e seu uso como inibidores micobacterianos | |
| BRPI0506400A8 (pt) | Uso de um composto para a fabricação de um medicamento para o tratamento de tuberculose latente | |
| TR200103497T2 (tr) | Beta2-adrenoseptör agonistler. | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
| TW200639156A (en) | New compounds | |
| BRPI0507076A (pt) | quinolinas substituìdas e seu uso como inibidores micobacterianos | |
| BRPI0614099B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto e o referido composto | |
| BRPI0612498A8 (pt) | derivados de quinolina como agentes antibacterianos | |
| SE0401763D0 (sv) | Compounds | |
| ATE514698T1 (de) | Tetracyclische azapyrazinoindoline als 5-ht2- liganden | |
| SG166799A1 (en) | Quinoline derivatives as antibacterial agents | |
| TH80291A (th) | การรักษาวัณโรคแฝง | |
| TH80291B (th) | การรักษาวัณโรคแฝง | |
| TH87171B (th) | อนุพันธ์ควิโนลีนเป็นสารต้านแบคทีเรีย | |
| TH87171A (th) | อนุพันธ์ควิโนลีนเป็นสารต้านแบคทีเรีย | |
| TH87918A (th) | อนุพันธ์ควินอลีนที่เป็นสารต้านแบคทีเรีย |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |